These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

893 related articles for article (PubMed ID: 22408430)

  • 21. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growing knowledge of the mTOR signaling network.
    Huang K; Fingar DC
    Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR-dependent cell survival mechanisms.
    Hung CM; Garcia-Haro L; Sparks CA; Guertin DA
    Cold Spring Harb Perspect Biol; 2012 Dec; 4(12):. PubMed ID: 23124837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
    Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
    Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
    J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
    Shaw RJ
    Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
    Sciascia Q; Pacheco D; McCoard SA
    J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK; Pizzo SV
    PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
    Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
    Julien LA; Carriere A; Moreau J; Roux PP
    Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nutrient signaling to mTOR and cell growth.
    Jewell JL; Guan KL
    Trends Biochem Sci; 2013 May; 38(5):233-42. PubMed ID: 23465396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.